Skip to main content

Market Overview

The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Share:
The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peaks

(Biotech stocks hitting 52-week highs on July 29)

  • Acasti Pharma Inc (NASDAQ: ACST)
  • Array Biopharma Inc (NASDAQ: ARRY)
  • GENMAB A/S/S ADR (NASDAQ: GMAB) (IPOed July 18)
  • Grifols SA - ADR ADR Class B (NASDAQ: GRFS)
  • Hologic, Inc. (NASDAQ: HOLX)
  • Novocure Ltd (NASDAQ: NVCR)
  • Odonate Therapeutics Inc (NASDAQ: ODT)
  • Repligen Corporation (NASDAQ: RGEN)

Down In The Dumps

(Biotech stocks hitting 52-week lows on July 29)

  • Acer Therapeutics Inc (NASDAQ: ACER)
  • Advaxis, Inc. (NASDAQ: ADXS)
  • Cancer Genetics Inc (NASDAQ: CGIX)
  • Champions Oncology Inc (NASDAQ: CSBR)
  • China SXT Pharmaceuticals Inc (NASDAQ: SXTC)
  • Genprex Inc (NASDAQ: GNPX)
  • Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA)
  • Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)(slumped in reaction to Sanofi SA (NASDAQ: SNY)'s decision to terminate their collaboration agreement regarding sotagliflozin that is being evaluated for Type 2 diabetes)
  • Myovant Sciences Ltd (NYSE: MYOV)
  • Neovasc Inc (NASDAQ: NVCN)
  • Neon Therapeutics Inc (NASDAQ: NTGN)
  • Neuralstem, Inc. (NASDAQ: CUR)
  • Novavax, Inc. (NASDAQ: NVAX)
  • Oncolytics Biotech, Inc. (NASDAQ: ONCY)
  • Personalis Inc (NASDAQ: PSNL)( IPOed June 20)
  • Cytori Therapeutics (NASDAQ: PSTV)
  • Proteostasis Therapeutics Inc (NASDAQ: PTI)
  • Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP)
  • TRACON Pharmaceuticals Inc (NASDAQ: TCON)
  • Unity Biotechnology Inc (NASDAQ: UBX)
  • Vistagen Therapeutics Inc (NASDAQ: VTGN)
  • Wave Life Sciences Ltd (NASDAQ: WVE) (reacted to a loss for Q2)
  • Xenetic Biosciences Inc (NASDAQ: XBIO)
  • Zafgen Inc (NASDAQ: ZFGN)

See Also: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Stocks In Focus

Coherus Wins Neulasta Biosimilar Patent Lawsuit

Coherus Biosciences Inc (NASDAQ: CHRS) said the U.S. Court of Appeals for the Federal Circuit has affirmed the decision of a U.S. district court that Coherus' Udenyca, Neulasta biosimilar, does not infringe Amgen, Inc. (NASDAQ: AMGN)'s asserted patent. Coherus launched Udenyca in the U.S. in January.

The stock gained 2.76% to $16.75 in after-hours trading.

Hepa Given Nod To Procced With IND Study Of CRV431 In NASH

Hepion Pharmaceuticals Inc (NASDAQ: HEPA), previously Contravir, said the FDA has authorized it to proceed with its planned investigational new drug application, or IND, opening study for CRV431 in non-alcoholic steatohepatitis following the review of its IND.

The company noted that the IND for NASH is in addition to the current open IND for hepatitis B virus.

The stock added 9.23% to $3.55 in after-hours trading.

Verastem Appoints Stuglik As CEO

Verastem Inc (NASDAQ: VSTM) announced the appointment of Brian Stuglik, a member of its board, as CEO. Stuglik has over three decades of experience in the pharmaceutical industry.

The stock fell 1.4% to $1.41 in after-hours trading.

Merck Combo Antibiotics Gets Backing Of European Regulatory Panel

Merck & Co., Inc. (NYSE: MRK) said the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted a positive opinion recommending Zerbaxa 3g dose – a combo drug of ceftolozane and tazobactam - for an additional indication for the treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, in adults.

The stock edged up 0.25% to $82.70 in after-hours trading.

Earnings

Medpace Holdings Inc )(NASDAQ: MEDP) reported second-quarter GAAP net income of 81 cents per share compared to 61 cents reported for the year-ago period and the consensus estimate of 66 cents per share. Revenues climbed 25.8% to $214.1 million, exceeding the $202.8 million consensus estimate.

The company issued above-consensus guidance for the fiscal year 2019.

The stock rallied 9.93% to $74.40 in after-hours trading.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported second-quarter EPS of 54 cents, higher than the 7 cents reported last year and the 11 cents per share consensus estimate. Revenues nearly doubled to $183.58 million

The stock gained 9.81% to $91.50 in after-hours trading.

On The Radar

Earnings

Eli Lilly And Co (NYSE: LLY) (before the market open)
Iradimed Corp (NASDAQ: IRMD) (before the market open)
Blueprint Medicines Corp (NASDAQ: BPMC) (before the market open)
Meridian Bioscience, Inc. (NASDAQ: VIVO) (before the market open)
Merck & Co., Inc. (NYSE: MRK) (before the market open)
Incyte Corporation (NASDAQ: INCY) (before the market open)
Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (before the market open)
NeoGenomics, Inc. (NASDAQ: NEO) (before the market open)
Pfizer Inc. (NYSE: PFE) (before the market open)
Amgen (after the market close)
AtriCure Inc. (NASDAQ: ATRC) (after the market close)
EXACT Sciences Corporation (NASDAQ: EXAS) (after the market close)
T2 Biosystems Inc (NASDAQ: TTOO) (after the market close)
BioTelemetry Inc (NASDAQ: BEAT) (after the market close)
Gilead Sciences, Inc. (NASDAQ: GILD) (after the market close)
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (after the market close)
Veracyte Inc. (NASDAQ: VCYT) (after the market close)

 

Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News FDA Top Stories Pre-Market Outlook Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com